Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage As In Situ Vaccine For Cancer At The Society For Immunotherapy Of Cancer Annual Meeting
11/15/2016 9:05:51 AM
Paris, France and Cambridge, Massachusetts, USA, November 14, 2016 – NANOBIOTIX (Euronext: NANO – ISIN:
FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of
cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively
stimulates the host immune system to attack tumor cells. These data from the ongoing NBTXR3 immuno-oncology
preclinical program were presented at one of the leading global immuno-oncology conferences, the 31st Annual
Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 9-13, 2016 in National Harbor,
Maryland, USA (Paris S., Pottier A., Levy L., and Lu B. Hafnium oxide nanoparticles, a radiation enhancer for in situ cancer
Laurent Levy, CEO of Nanobiotix, commented: “These exciting data show that NBTXR3 could be a potential game
changer in Immuno-oncology combination landscape. This raises the possibility of synergies between NBTXR3,
radiotherapy and immunotherapies. On the top of existing core developments of our product as a single agent, this is
opening new doors for industrial collaborations.”
Data presented showing the potential of NBTXR3 in Immuno-Oncology
During the presentation, Nanobiotix scientists and Dr. Bo Lu, MD, Director of the Molecular Radiation Biology in the
Department of Radiation Oncology at the Thomas Jefferson University Hospital in Philadelphia, presented study results
which demonstrate that radiotherapy with NBTXR3 elicits a marked enhancement of Immunogenic Cell Death (ICD)
compared to radiotherapy alone across different cancer cell lines, in radioresistant or radiosensitive models.
In a second experiment, the phenomenon known as the abscopal effect was evaluated (i.e. an effect outside the scope
of the localized treatment). Two tumors were implanted on both sides of mice, and subsequently only one tumor was
treated with NBTXR3-radiation therapy. As a result, both tumors demonstrated volume shrinkage. Specifically, the study
showed that use of NBTXR3 in combination with radiotherapy resulted in a control on the untreated tumor and a
statistically significant increase of overall survival. No abscopal effect was observed in control groups and group treated
with radiation therapy alone.
A third experiment has demonstrated that NBTXR3 combined with radiotherapy could be used to create a vaccine ex
vivo with a higher rate of long term vaccination success when compared to radiotherapy alone.
Elsa Borghi, CMO of Nanobiotix commented: “Although immunotherapies hold great promise in treating cancer, one of
the main barriers is that most of tumors do not provoke an immune response, which renders immunotherapy ineffective
in many patients. The findings from this research indicate that NBTXR3 could have the potential to transform a tumor
into an in situ vaccine. It could convert an immunologically ‘cold’ tumor, which does not provoke an immune response,
to a ‘hot’ tumor, which induces an immune response and therefore provokes a host immune response to attack tumor
NBTXR3 competitive positioning in Immuno-Oncology
Radiotherapy is an established standard of care in many solid tumor types (approximately 60% of all cancer patients
receive radiotherapy). Compared to other products used for priming of the tumor, currently in development for
Immuno-Oncology, NBTXR3 could have a number of advantages: a physical and universal mode of action that could be
used widely across oncology, one time local injection, a good fit within existing medical practice already used a base for
cancer treatment, limited or no systemic toxicity, and a well-established manufacturing process.
Radiotherapy is often given within the first lines of cancer treatment, compare to most current positioning of immunooncology
development in a later stage treatment. A successful approach using NBTXR3 in immuno-oncology could make
it a key player by offering treatment options in earlier stages of the disease.
Taken together, these data indicate that radiotherapy in combination with NBTXR3 could play a key role in immunooncology
and could be used in synergy with several immuno-oncology approaches to increase patient responses across
many different types of cancer.
NBTXR3 current clinical development as a single agent
Outside immuno-oncology field and as a single agent, NBTXR3 is in late stage clinical development, for its capability to
enhance the dose of radiotherapy within the tumor and more efficiently destroy cancer cells. Worldwide clinical
development is currently covering seven patient populations and a first market approval has been filed in EU in August
comments powered by